Every year, our Fierce Biotech team evaluates hundreds of early-stage companies from around the world. Only the most promising are selected for our annual list of Fierce 15 honorees. That list is based on a variety of factors like the strength of the company’s technology, partnerships, venture backers and a competitive market position. This year’s 15 honorees were recognized at the Fierce Biotech Summit. In this episode, we'll hear directly from them about their company’s work, what makes it unique, and what drives them.  

We'll also take you to the Fierce Biotech Summit. It happened in Boston on September 19 and 20, and covered drug development from the earliest stage of research to FDA approval. So if you missed the summit, this episode covers some event highlights including a panel moderated by Fierce Pharma senior staff writer Angus Liu on the future of gene editing and a session moderated by managing editor Querida Anderson on battling biotech's bear market.

To learn more about topics in this episode: 

• Special Report: Fierce Biotech's 2022 Fierce 15
• The Fierce Biotech Summit: Where Biotech Innovation Happens 
• Fierce Biotech Summit: As the biotech market teases turning a corner, stakeholders say we're in a 'new normal' 
• Servier severs CAR-T collab with Allogene, handing back rights outside the US to 3 candidates
• Months after exiting clinical hold, Pfizer readies to resume dosing in phase 3 gene therapy trial
• ESMO: BioNTech's CAR-T response rate falls in fresh cut of early-phase data

The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.